Magnesium–Ibogaine Therapy in Veterans with Traumatic Brain Injuries

About this resource

This page closely follows the prospective observational study reported by Cherian and colleagues in 2024. The study enrolled 30 male US special operations veterans with histories of head injury and repeated blast or combat exposure, and evaluated daily functioning, PTSD symptoms, depression, anxiety, neuropsychological performance, and safety before and after a magnesium-assisted ibogaine protocol (MISTIC).

Crucially, this was not a randomized controlled trial. Participants entered the study after independently deciding to receive care at a facility in Mexico, making it a single-group, open-label observation. Improvements were measured, but the contributions of ibogaine, magnesium, prior expectations, travel, coaching, group activities, and complementary wellness activities cannot be separated. The study did not establish that traumatic brain injury itself was healed or repaired, or that the same outcomes would occur in the general patient population.

Study design

Thirty-four people were screened, 33 enrolled, and 30 ultimately completed baseline and post-treatment assessments between November 2021 and September 2022. All were men, with a mean age of 44.9 ± 7.5 years. Traumatic brain injury was classified as mild in 28 participants, moderate in one, and more than moderate in one. Participants reported a lifetime mean of 38.6 ± 52.4 TBIs, 5.5 ± 3.0 combat deployments, and 7.7 ± 4.8 years since leaving military service. Structured interviews found that 23 met criteria for PTSD, 15 for major depressive disorder, 14 for an anxiety disorder, and 15 for alcohol use disorder.

Independently of the research, participants had booked MISTIC at Ambio Life Sciences in Mexico with nonprofit grant support. Stanford did not administer the treatment. The facility and research team conducted blood tests, ECGs, and physical and psychiatric assessments, and excluded cardiovascular, hepatic, and renal problems, psychotic symptoms, risk of suicidal behavior, and other specified conditions. The facility directed participants to discontinue several medications of concern for drug interactions.

The primary outcome was change in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2.0) from baseline to immediately after administration; WHODAS at one month was secondary. Other measures included the clinician-rated CAPS-5 for PTSD, MADRS for depression, and HAM-A for anxiety. Neuropsychological tests assessed attention, memory, processing speed, executive function, language, and other domains. Analyses used linear mixed-effects models with age, combat exposure, and number of TBIs as fixed effects, and corrected multiple comparisons using the false discovery rate. No prospective power calculation was conducted because this was an observational study.

Content

MISTIC and the surrounding program

Individual coaching before treatment addressed expectations, concerns, intention setting, and related topics. At the facility, participants could also choose complementary activities such as sweat lodge, massage, yoga, Reiki, breathwork, and meditation. No psychotherapy was conducted during administration; participants wore eyeshades for a self-directed experience, followed by integration activities the next day. These elements were part of the actual intervention setting and may have influenced the results.

The ibogaine hydrochloride used was described as more than 98% pure. Under fasting conditions, 1 g of magnesium sulfate was administered intravenously 1–2 hours before ibogaine. Ibogaine began with a 2–3 mg/kg test dose, followed by an additional dose approximately 40 minutes later according to response, for a total below 14 mg/kg within two hours. The actual mean dose was 12.1 ± 1.2 mg/kg. Magnesium was administered again approximately 12 hours later, together with antioxidant and metabolic-support substances. One participant received an additional 4 mg/kg of ibogaine 12 hours after the first administration.

A physician trained in advanced cardiovascular life support and a nurse or emergency medical technician were present at a ratio of at least one staff member for every two patients. Blood pressure and oxygen saturation were checked for 12–16 hours after administration, and QTc was continuously viewed on a five-lead ECG. The paper’s cardiac safety observations apply to this selected group under these monitoring and support conditions.

Assessment timeline

Remote baseline assessment began between two months and one week before treatment, followed by in-person clinical and neuropsychological assessment at Stanford 2–3 days before administration. Participants received MISTIC in Mexico, returned to Stanford for immediate assessment 4–5 days after administration, and underwent follow-up one month later. At one month, four participants had not completed WHODAS and three had not completed neuropsychological testing; the number of missing observations varied by test.

Results

Daily functioning and psychiatric symptoms

Mean WHODAS total score decreased from 30.2 ± 14.7 at baseline to 19.9 ± 16.3 immediately afterward (adjusted p < 0.001, Cohen’s d = 0.74). At one month it was 5.1 ± 8.1; the difference from baseline had adjusted p < 0.001 and d = 2.20. Every subdomain showed a statistical improvement immediately afterward, with the largest effect size in the cognition domain at d = 0.96.

CAPS-5 changed from 31.7 ± 12.5 to 3.9 ± 4.8 immediately afterward and 4.8 ± 7.9 at one month, with one-month d = 2.54. MADRS changed from 25.6 ± 8.7 to 2.8 ± 3.3 and 3.8 ± 6.0, with one-month d = 2.80. HAM-A changed from 20.8 ± 8.5 to 3.6 ± 3.4 and 3.9 ± 4.6, with one-month d = 2.13. Every comparison with baseline had adjusted p < 0.001.

Using measure-specific definitions, the authors reported response rates of 93–100% immediately afterward and 93–100% at one month, and remission rates of 83–86% immediately afterward and 83–86% at one month. These were exploratory totals among 29 participants after excluding one person who was already within remission criteria on the relevant scale, not comparisons with a control group.

The proportion scoring at least 1 on the MADRS suicidal-ideation item decreased from 47% at baseline to 0% immediately afterward and 7% at one month. This was not an analysis designed around a dedicated suicidal-ideation measure as a primary outcome, and the authors themselves called for cautious interpretation as an exploratory finding. It does not establish a suicide-prevention effect.

Neuropsychological assessment

Reported effect sizes for processing speed were d = 0.97 immediately afterward and d = 1.34 at one month; executive-function measures generally improved by approximately d = 0.31–1.22. Statistical changes were also found in attentional accuracy, visual memory, and verbal memory at one month, while semantic fluency did not change significantly. No decline from baseline was reported in the tested domains.

The authors discussed the possibility that improvements on objective tests are harder to explain by expectation alone. Some tests, however, may show practice effects upon repetition. Although the study attempted to reduce these effects by using alternate forms and other measures, the absence of an untreated control group means that practice effects and natural fluctuation cannot be fully excluded.

The large observed effect sizes describe the magnitude of change; a causal treatment effect cannot be established from before-and-after differences in a single group. Participants were highly motivated to receive treatment and were medically screened special operations veterans. Persistence beyond one month was not measured.

Limitations

The principal constraint is the absence of randomization, a control group, and blinding. Participants independently chose overseas treatment, so expectations, selection bias, international travel, coaching, group preparation, complementary activities, and other nonspecific factors cannot be separated from the pharmacologic effects of MISTIC. The respective contributions of ibogaine and magnesium were also not compared.

The sample was small at 30 participants, nearly all White men, and concentrated among physically healthy former elite military personnel. TBI and functional impairment were mild on average. Results cannot be generalized to more severe TBI, women, the broader veteran population, people with cardiovascular, hepatic, or renal disease, or more diverse groups. Mean improvements persisted, but some participants showed renewed psychiatric symptoms between the immediate assessment and one month, supporting the need for longer follow-up.

Neuropsychological testing was subject to missing data and possible practice effects. Suicidal ideation was an exploratory single-item analysis, not a validation with a dedicated scale. The sample was also too small to detect rare serious adverse events. The paper did not demonstrate radiographic repair of TBI lesions, disease modification, long-term relapse prevention, or superiority to existing treatments.

The disclosures state that some authors are inventors on patent applications concerning safe administration of MISTIC or its use in conditions related to brain aging. Three were shareholders of the treatment provider, Ambio Life Sciences, and inventors on related provisional patent applications. The Stanford group reported receiving no funding from VETS or Ambio. These disclosures do not automatically invalidate the results, but they heighten the need for independent replication.

Safety

No unexpected adverse events or serious treatment-related adverse events were reported in the study. Bradycardia, tachycardia, hemodynamic instability, and clinically apparent QT prolongation detectable qualitatively on the monitor were not reported. This was not, however, a trial comparing quantitative QTc changes with a control group, and it did not prove that serious cardiotoxicity cannot occur.

Every participant experienced transient cerebellar signs such as mild ataxia or intention tremor, which resolved within 24 hours. Symptoms requiring treatment during the experience were headache in 12 participants (40%), nausea in 7 (23%), anxiety in 3 (10%), hypertension in 2 (7%), and insomnia in 1 (3%).

The safety findings arose under conditions that included prior blood testing and ECG, exclusion of cardiovascular, hepatic, and renal disease and other conditions, discontinuation of medications with interaction concerns, magnesium co-administration, staff capable of advanced life support, and continuous ECG monitoring. The authors suggested that magnesium might contribute to cardiac protection, but the study had no comparison group without magnesium and did not test that protective effect.

Source and rights

Original source: Cherian KN, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. 2024;30:373–381. DOI: 10.1038/s41591-023-02705-w. PMID 38182784; PMCID PMC10878970. Clinical trial registration NCT04313712.

The original article is published under Creative Commons Attribution 4.0 International (CC BY 4.0). This page follows the source but does not reproduce every item in the tables, test procedures, references, or supplements verbatim. It preserves the study timeline and the distinctions among observations, author interpretations, safety findings, and limitations while rendering the principal content for English readers.